In a significant decision, the Federal Circuit has denied an appeal from Purdue Pharma, the bankrupt manufacturer of OxyContin, which sought to invoke patent laws to prevent the introduction of a generic, “crush-resistant” version of its painkiller. This move marks one of the final judicial actions of the past year by the Federal Circuit.
The legal battle highlights ongoing issues in the pharmaceutical industry, particularly concerning patent rights and the introduction of generic drugs. In this case, Purdue Pharma’s appeal aimed to maintain market exclusivity for its innovative formulation by blocking competitors from launching similar alternatives. The Federal Circuit’s rejection of this appeal opens the door for the entry of generic competitors in the market.
Further details can be explored in the original article on Law360.